Partial portal vein ligation plus thioacetamide: A method to obtain a new model of cirrhosis and chronic portal hypertension in the rat

Journal of Gastrointestinal Surgery

Volumn 11, Issue 2, 2007, Pages 187-194

  Méndez López, Marta ^a   Méndez, Magdalena ^a   Sánchez Patán, Fernando ^b   Casado, Isabel ^c   Aller, Maria Angeles ^b   López, Laudino ^a   Corcuera, Maria Teresa ^c   Alonso, Maria Jose ^c   Nava, Maria Paz ^b   Arias, Jaime ^b   Arias, Jorge Luis ^a  

^a UNIVERSITY OF OVIEDO   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

Author keywords

Cirrhosis; Partial portal vein ligation; Portal hypertension; Portosystemic collateral circulation; Thioacetamide

Indexed keywords

THIOACETAMIDE;

ANIMAL; ARTICLE; BODY WEIGHT; CHRONIC DISEASE; COLLATERAL CIRCULATION; DISEASE MODEL; EXPERIMENTAL LIVER CIRRHOSIS; LIGATION; LIVER; MALE; MESENTERIC VEIN; PATHOLOGY; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN; RAT; WISTAR RAT;

ANIMALS; BODY WEIGHT; CHRONIC DISEASE; COLLATERAL CIRCULATION; DISEASE MODELS, ANIMAL; HYPERTENSION, PORTAL; LIGATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MESENTERIC VEINS; PORTAL VEIN; RATS; RATS, WISTAR; THIOACETAMIDE;

EID: 34548439834     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-006-0063-1     Document Type: Article

References (37)

1. Muller A, Machnik F, Zimmermann T, Schubert H. Thioacetamide-induced cirrhosis-like lesions in rats-usefulness and reliability of this animal model. Exp Pathol 1998;34:229-236.
2. Li X, Benjamin IS, Alexander B. Reproducible production of thioacetamide-induced macronodular cirrhosis in the rat with no mortality. J Hepatol 2002;36:488-493.
3. Mas MR, Comer B, Oncu K, Vural SA, Akay C, Tasci I, Ozkomur E, Serdar M, Mas N, Alcigir G, Yener N. The effect of taurine treatment on oxidative stress in experimental liver fibrosis. Hepatol Res 2004;28:207-215.
4. Benoit JN, Barrowman JA, Harper SL, Kvietys PR, Granger DN. Role of humoral factors in the intestinal hyperemia associated with chronic portal hypertension. Am J Physiol (Gastrointest Liver Physiol 10) 1984;247:G486-G493.
5. Lopez-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor α: A major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995;108:761-767.
6. Orloff MJ. Portal hypertension and portocaval shunt. In WW Souba, DW Wilmore Eds., Surgical research vol. 49 London: Academic, 2001, pp. 637-701.
7. Lopez-Talavera JC, Cadelina G, Merrill WW, Groszmann RJ. Role of tumor necrosis factor-alpha in the circulatory abnormalities of cirrhotic rats. Hepatology 1995;22:256A.
8. Sikuler E, Kravetz D, Groszmann RJ. Evolution of portal hypertension and mechanisms involved in its maintenance in a rat model. Am J Physiol (Gastrointest Liver Physiol 11) 1985;248:G618-G625.
9. McMathuna P, Vlavianos P, Westaby D, Williams R. Pathophysiology of portal hypertension. Dig Dis 1992;10(suppl 1):3-15.
10. Chojkier M, Groszmann RJ. Measurement of portal-systemic shunting in the rat by using γ-labeled microspheres. Am J Physiol (Gastrointest Liver Physiol 3) 1981;240:G371-G375.
11. Hori N, Okanoue T, Sawa Y, Mori T, Kashima K. Hemodynamic characterization in experimental liver cirrhosis induced by thioacetamide administration. Dig Dis Sci 1993;38:2195-2202.
12. Sherlock S. The portal venous system and portal hypertension. In S. Sherlock Ed., Diseases of the liver and biliary system 8th ed. London: Blackwell, 1989 pp. 151-207).
13. 4 levels in short-term prehepatic portal hypertension in rats. Dig Dis Sci 2000;45:1865-1871.
14. Dieguez B, Aller MA, Nava MP, Arias JL, Lopez L, Arias J. Chronic portal hypertension in the rat by triple-portal stenosing ligation. J Inves Surg 2002;15:329-336.
15. Castañeda B, Dubernardi-Venon W, Bandi JC, Andreu V, Perez del Pulgar S, Moitinho E, Pizcueta P, Bosch J The role of portal pressure in the severity of bleeding in portal hypertensive rats. Hepatology 2000;31:581-586.
16. Kravetz D, Sikuler E, Groszmann RJ. Splanchnic and systemic hemodynamics in portal hypertensive rats during hemorrhage and blood volume restitution. Gastroenterology 1986;90:1232-1240.
17. Knodell RG, Ishak KG, Black WC, Chen TS, Graig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981;1:431-435.
18. Desmet VJ, Gerber M, Hoofnagle JH, Manns M, Schever PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1519.
19. Nakata M, Nakamura K, Koda Y, Kaminou T, Ugami M, Kaneda K, Yamada R. Hemodynamics in the microvasculature of thioacetamide-induced cirrhotic rat livers. Hepato-Gastroenterol 2002;49:652-656.
20. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004 2004;18:353-372.
21. Fernandez M, Vizzutti F, Garcia-Pagan JC, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevent portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-894.
22. Moreau R. VEGF-induced angiogenesis drives collateral circulation in portal hypertension. J Hepatol 2005;43:6-8.
23. Diez-Arias JA, Aller MA, Palma MD, Arias JL, Muñiz E, Sanchez M, Arias J. Increased duodenal mucosa infiltration by mast cells in rats with portal hypertension. Dig Surg 2001;18:34-40.
24. Prieto I, Aller MA, Santamaria L, Nava MP, Madero R, Perez-Robledo JP, Arias J. Prehepatic portal hypertension produces increased mast cell density in the small bowel and in mesenteric lymph node in the rat. J Gastroenterol Hepatol 2005;20:1025-1031.
25. Lopez L, Gonzalez-Pardo H, Aller MA, Nava MP, Duran HJ, Arias J, Arias JL. Actividad de citocromo oxidasa esplacnica en ratas con hipertensión portal. Rev Esp Enf Dig Madrid 2001;93:794-799.
26. Wang JJ, Gao G-W, Gao R-Z, Liu Ch-A, Ding X, Yao Z-X. Effects of tumor necrosis factor, endothelin and nitric oxide on hyperdynamic circulation of rats with acute and chronic portal hypertension. World J Gastroenterol 2004;10:689-693.
27. Dashti H, Jeppsson B, Hägerstrand I, Hultberg B, Srinivas U, Abdulla M, Bengmark S. Thioacetamide-and carbon tetrachloride-induced liver cirrhosis. Eur Surg Res 1989;21:83-91.
28. Chen S, Wang H-T, Yang B, Ou, Q-J. Protective effects of recombinant human growth hormone on cirrhotic rats. World J Gastroenterol 2004;10:2894-2897.
29. Medina J, Arroyo AG, Sanchez-Madrid F, Moreno-Otero R. Angiogenesis in chronic inflammatory liver disease. Hepatology 2004;39:1185-1195.
30. Suneyama TK, Ohba K, Zen Y, Sato Y, Niwa H, Minato H, Nakanuma Y. A comparative histological and morphometric study of vascular changes in idiopathic portal hypertension and alcoholic fibrosis/cirrhosis. Histopathology 2003;43:55-61.
31. Ward NL, Haninec AL, Van Slyke P, Sled JG, Sturk C, Henkelman RM, Wanless IR, Dumont DJ. Angiopoietin-1 causes reversible degradation of the portal microcirculation in mice: Implications for treatment of liver disease. Am J Pathol 165:889-899.
32. Kishore R, Quin G, Luedemann C, Bord E, Hanley A, Silver M, Goukassian D, Losordo DW. The cytoskeletal protein ezrin regulates EC proliferation and angiogenesis via TNF-alpha-induced transcriptional repression of cyclin A. J Clin Invest 2005;115:1785-1796.
33. Ridnour LA, Isenberg JS, Espey MG, Thomas DD, Roberts DD, Wink DA. Nitric oxide regulates angiogenesis through a functional switch involving thrombospondin-1. Proc Natl Acad Sci USA 2005;102:13147-13152.
34. Prieto I, Jimenez F, Aller MA, Nava MP, Vara E, Garcia C, Arias J. Tumor necrosis factor-alpha, interleukin-1 beta and nitric oxide: induction of liver megamitochondria in prehepatic portal hypertensive rats. World J Surg 2005;29:903-908.
35. Aller MA, Vara E, Garcia C, Palma MD, Arias JL, Nava MP, Arias J. Proinflammatory liver and antiinflammatory intestinal mediators involved in portal hypertensive rats. Mediators Inflamm 2005;2:101-111.
36. Palma MD, Aller MA, Vara E, Nava MP, Garcia C, Arias-Diaz J, Balibrea JL, Arias J. Portal hypertension produces an evolutive hepato-intestinal pro- and anti-inflammatory response in the rat. Cytokine 2005;31:213-226.
37. Corcuera MT, Nava MP, Angulo A, Aller MA, Gomez F, Casado I, Alonso MJ, Arias J. Splanchnic remodeling secondary to experimental prehepatic portal hypertension. An Med Inter 2005;22:317-322.